Natco Pharma continued to witness selling pressure even on Thursday's trading session after the Delhi High Court allowed the interim injunction application of FMC Corporation on Chlorantraniliprole (CTPR).
At around 2.34 PM, Natco is trading at Rs1064.75 per piece down by 2.07% on Sensex. The stock has touched an intraday low of Rs1060 per piece in the early deals.
Natco has dived by as much as 7% on Wednesday after the Delhi HC orally pronounced judgment in the interim injunction application filed by FMC Corporation on CTPR.
In its regulatory filing, Natco said, "The Hon'ble Court said that it has allowed the application of FMC Corporation."
"The full copy of the Judgment is yet to become available. Natco will review all its options after the full Judgment becomes available to it," Natco said.
Earlier in February this year, Natco received registration approval for Chlorantraniliprole from Central Insecticide Board & Registration Committee to use the ingredient in pest management products.
Chlorantraniliprole is an active ingredient used in products.
FMC also uses CTPR in its products under their brands Coragen and Ferterra.
However, FMC later sued Natco in the Delhi HC alleging patent infringement.